Cost effectiveness of palivizumab in children with congenital heart disease in Germany

References

• Simoes E. Respiratory syncytial virus infection. Lancet 1999;354: 847–852.
   PubMed Web of Science ®Google Scholar
• Hall C. Respiratory syncytial virus . In: Feigin R, Cherry J, eds. Infectious Diseases. Philadelphia: W.B. Saunders, 1998.
   Google Scholar
• Berner R, Schwoerer F, Schumacher RF, Community and nosocomially acquired respiratory syncytial virus infection in a German paediatric hospital from 1988 to 1999. Eur J Pediatr 2001;160:541–547.
   PubMed Web of Science ®Google Scholar
• Liese JG, Grill E, Fischer B, Munich RSV Study Group. Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr 2003;162:230–236.
   PubMed Web of Science ®Google Scholar
• Canfield S, Simoes E. Prevention of respiratory syncytial virus (RSV) infection: RSV immune globulin intravenous and palivizumab. Pediatric Ann 1999;28:507–514.
   PubMed Web of Science ®Google Scholar
• Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 1995;126:212–219.
   PubMed Web of Science ®Google Scholar
• Navas L, Wang E, de Carvalho V, Robinson J. Pediatric Investigators Collaborative Network on Infections in Canada: improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. J Pediatr 1992;121:348–354.
   PubMed Web of Science ®Google Scholar
• Moler FW, Khan AS, Meliones JN, Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: a recent experience. Crit Care Med 1992;20:1406–1413.
   PubMed Web of Science ®Google Scholar
• Khongphatthanayothin A, Wong PC, Samara Y, Impact of respiratory syncytial virus infection on surgery for congenital heart disease; postoperative course and outcome. Crit Care Med 1999;27:1974–1981.
   PubMed Web of Science ®Google Scholar
• Altman CA, Englund JA, Demmler G, Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of preoperative screening. Pediatr Cardiol 2000;21:433–438.
   PubMed Web of Science ®Google Scholar
• Malhotra A, Krilov L. Influenza and respiratory syncytial virus. Update on infection, management and prevention. Pediatr Clin North Am 2000;47:353–372.
   PubMed Web of Science ®Google Scholar
• Bont L, Aalderen WM, Kimpen JL. Long-term consequences of respiratory syncytial virus (RSV) bronchiolitis. Paediatr Respir Rev 2000;1:221–227.
   PubMedGoogle Scholar
• European Medicines Agency. http://www.emea.eu.int/humandocs/Humans/EPAR/synagis/Synagis.htm.
   Google Scholar
• Feltes TF, Cabalka AK, Meissner HC, Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532–540.
   PubMed Web of Science ®Google Scholar
• Palivizumab prescribing information.
   Google Scholar
• Nuijten, MJC. Cost-effectiveness of fluvoxamine in the treatment of recurrent depression in France. Pharmacoeconomics 1998;14: 433–445.
   PubMed Web of Science ®Google Scholar
• Nuijten MJ. The selection of data sources for use in modelling studies. Pharmacoeconomics 1998;13:305–316.
   PubMed Web of Science ®Google Scholar
• Brecht JG, Jenke A, Kohler ME, Recommendations of the German Society of Clinical Pharmacology and Therapy for implementing and evaluating pharmaco-economic studies. Med Klin (Munich) 1995;90:541–556.
   PubMedGoogle Scholar
• International Society for Pharmacoeconomics and Outcomes Research (ISPOR). German recommendations on health economic evaluation studies. Revised version of the Hannover Consensus, 1995.
   Google Scholar
• Simoes EA, Sondheimer HM, Top FHJr, ; Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group. J Pediatr 1998;133: 492–499.
   PubMed Web of Science ®Google Scholar
• Rodriguez WJ, Parrott RH. Ribavirin aerosol treatment of serious respiratory syncytial virus infection in infants. Infect Dis Clin North Am 1987;1:425–439.
   PubMedGoogle Scholar
• Nuijten MJ, Wittenberg W, Lebmeier M. Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: A UK analysis. Pharmacoeconomics 2007;25:55–71.
   PubMed Web of Science ®Google Scholar
• Statistisches bundesamt Deutschland. www.destatis.de.
   Google Scholar
• Wren C, O'Sullivan JJ. Survival with congenital heart disease and need for follow up in adult life. Heart 2001;85:438–443.
   PubMed Web of Science ®Google Scholar
• Greenough A, Alexander J, Burgess S, Health care utilisation of prematurely born, preschool children related to hospitalization for RSV infection. Arch Dis Child 2004;89:673–678.
   PubMed Web of Science ®Google Scholar
• Roeckl-Wiedmann I, Liese JG, Grill E, Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany. Eur J Pediatr 2003:162;237–244.
   PubMed Web of Science ®Google Scholar
• 3M Medica - Health Information Systems. DRG online grouper http://www.grdrg.de/GrouperCGI/OnlineGrouper.exe.
   Google Scholar
• Graf von der Schulenburg JM, Greiner W, Molitor S, Cost of asthma therapy in relation to severity. An empirical study. Med Klin (Munich) 1996;91:670–676.
   PubMedGoogle Scholar
• Organisation for Economic Co-operation and Development (OECD). OECD Employment Outlook 2004. www.oecd.org.
   Google Scholar
• Laufer F. Thresholds in cost-effectiveness analysis – more of the story. Value Health 2005;8:886–887.
   Web of Science ®Google Scholar
• Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics 2004;114:1606–1611.
   PubMed Web of Science ®Google Scholar
• Wegner S, Vann JJ, Liu G, Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program. Pediatrics 2004;114:1612–1619.
   PubMed Web of Science ®Google Scholar
• Lofland JH, O'Connor JP, Chatterton ML, Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis. Clin Ther 2000;22:1357–1369.
   PubMed Web of Science ®Google Scholar
• Resch B, Gusenleitner W, Nuijten MJC, Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria. Clin Ther 2008;30:749–760
   PubMed Web of Science ®Google Scholar